FDA launches lawsuits against stem cell clinics after patients rendered blind
May 10, 2018Medical Communications, Sales and Marketing FDA, Stem cells, US, macular degeneration, pharma
At the request of the FDA, The US Department of Justice has launched legal action seeking to shut down stem …
Lodo and Roche go digging for drug candidates, after $1bn deal
May 10, 2018Sales and Marketing Genentech, Roche, biotech, drugs, pharma, pharmaceutical
Discovering potential therapeutics from natural sources has been a constant throughout the evolution of medicine, Lodo Therapeutics, however, has taken …
Novartis’ $1.2m payment to Trump’s lawyer raises more questions than answers
May 10, 2018Medical Communications Essential Consultants, Michael Cohen, Novartis, President trump, Trump, biotech, drugs, pharma, pharmaceutical
Novartis payment to President Trump’s personal lawyer, Michael Cohen, had seemed fairly odd from the beginning – with many asking …
The new and improved Spring 2018 edition of Pharmafile is available to read online now!
May 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CNS, Cancer, Pharmafocus, cardiovascular, cvd, oncology, pharmafile
The Spring 2018 edition of Pharmafile, our long-running bi-annual guide to the latest trends, projections and thought leadership positions in …
BenevolentAI names former UK Minister as new Group CEO
May 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, BenevolentAI, Facebook, UK, appointment, google
Health and drug development-focused artificial intelligence firm BenevolentAI has announced that former UK Minister for Internet Security and Safety Joanna …
GSK’s CFO chooses to exit company
May 9, 2018Medical Communications GSK, biotech, drugs, pharma, pharmaceutical
Simon Dingemans has been Chief Financial Officer at GSK since 2011 but has now chosen to retire from the position …
Valeant seeks clean slate with rebrand, new company name
May 9, 2018Medical Communications, Research and Development Valeant, pharma
In the latest attempt to reverse its ailing fortunes and distance itself from its polluted brand, Canadian pharma firm Valeant …
Old osteoporosis drug could be used to treat hair loss
May 9, 2018Research and Development biotech, drugs, hair loss, pharma, pharmaceutical
Researchers from the University of Manchester’s Centre for Dermatology Research have made a breakthrough towards the holy grail of the …
Faron’s stock freefalls by 80% after key drug failure
May 9, 2018Research and Development ARDS, Faron, acute respiratory distress syndrome, pharma, traumakine
Faron Pharmaceuticals has seen its share price plummet by more than 80% after it emerged that its recombinant human interferon …
Novartis caught in the Stormy Daniels affair, after huge payment to Trump’s lawyer
May 9, 2018Medical Communications, Research and Development Cohen, Novartis, President trump, Trump, biotech, drugs, pharma, pharmaceutical
Novartis has suddenly found itself embroiled in the Stormy Daniels affair, after the lawyer representing her, Michael Avenatti, included the …
European approval for tablet formulation of Lynparza in ovarian cancer
May 8, 2018Research and Development, Sales and Marketing AstraZeneca, Cancer, EMA, Europe, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) has been approved for use in Europe, it has emerged, …
All eyes on dry eye disease
May 8, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing TopiVert, dry eye disease, eye, pharma
Dr Matthew Fyfe, Head of Chemistry and Intellectual Property at TopiVert, gives an illuminating look into the latest developments in …
FDA approves Novartis combo in rare thyroid cancer subtype
May 8, 2018Manufacturing and Production, Sales and Marketing Cancer, FDA, Tafinlar, mekinist, thyroid cancer
The FDA has announced its decision to approve the use of Novartis’ combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in …
J&J’s ketamine-based antidepressant showed mixed success at Phase 3
May 8, 2018Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma
Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …
Genmab and Janssen’s Darzalex combo scores FDA approval in multiple myeloma
May 8, 2018Manufacturing and Production, Sales and Marketing FDA, Genmab, Janssen, US, darzalex, multiple myeloma, pharma
Genmab and Janssen have revealed that their combination of Darzalex (daratumumab) with bortezomib (Velcade), melphalan, and prednisone (VMP) has received …
AstraZeneca jettisons schizophrenia drug for $538 million
May 8, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Luye Pharma, Seroquel, pharma, schizophrenia
AstraZeneca has confirmed it has signed a deal to jettison its schizophrenia drug Seroquel and its extended release version Seroquel …
It’s official: Takeda to buy Shire for £46 billion
May 8, 2018Manufacturing and Production, Sales and Marketing Shire, Takeda, acquisition, pharma
After more than a month of uncertainty, Takeda has finally confirmed it has managed to successfully acquire Shire, agreeing on …
Top Ten most popular articles on Pharmafile.com this week
May 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia
It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …
Los Angeles becomes latest US city to sue pharma over opioid crisis
May 4, 2018Medical Communications, Sales and Marketing Los Angeles, opioid crisis, pharma
The city of Los Angeles has levied legal action against a number of pharmaceutical firms for their role in advancing …
Mallinckrodt gets two thumbs down from FDA for jaundice drug
May 4, 2018Medical Communications, Sales and Marketing InfaCare, Mallinckrodt, biotech, drugs, pharma, pharmaceutical
Mallinckrodt paid $80 million, with a further $345 million dependent on milestones, to acquire InfaCare in the hope that the …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
